STOCK TITAN

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags

AbCellera, Viking Global Investors, and ArrowMark Partners have collaborated to launch new biotech companies focusing on advancing antibody drug programs. The partnership aims to create assets in the area of immunology, with Viking and ArrowMark overseeing program selection and funding, while AbCellera leverages its expertise in discovering and developing antibody medicines. Successful programs will lead to the creation of new companies, with AbCellera participating as an equity founding partner.

AbCellera, Viking Global Investors e ArrowMark Partners hanno collaborato per lanciare nuove aziende biotecnologiche focalizzate sullo sviluppo di programmi di farmaci anticorpali. La partnership mira a creare risorse nel campo dell'immunologia, con Viking e ArrowMark che supervisionano la selezione e il finanziamento dei programmi, mentre AbCellera sfrutta la sua esperienza nella scoperta e nello sviluppo di medicinali anticorpali. I programmi di successo porteranno alla creazione di nuove aziende, con AbCellera che partecipa come partner fondatore con partecipazione azionaria.
AbCellera, Viking Global Investors y ArrowMark Partners han colaborado para lanzar nuevas empresas biotecnológicas que se centran en avanzar en programas de drogas anticuerpos. La asociación tiene como objetivo crear activos en el área de inmunología, con Viking y ArrowMark supervisando la selección y la financiación de los programas, mientras que AbCellera aprovecha su experiencia en el descubrimiento y desarrollo de medicamentos de anticuerpos. Los programas exitosos conducirán a la creación de nuevas empresas, con AbCellera participando como socio fundador de capital.
AbCellera, Viking Global Investors, 그리고 ArrowMark Partners는 항체 약물 프로그램을 발전시키기 위해 새로운 바이오텍 회사를 출범시키기 위해 협력하였습니다. 이 파트너십은 면역학 분야에서 자산을 창출하는 것을 목표로 하며, Viking과 ArrowMark가 프로그램 선택과 자금 조달을 감독하는 동안 AbCellera는 항체 의약품의 발견과 개발에서의 전문성을 활용합니다. 성공적인 프로그램은 AbCellera가 지분 창립 파트너로 참여하는 새로운 회사의 창설로 이어질 것입니다.
AbCellera, Viking Global Investors et ArrowMark Partners ont collaboré pour lancer de nouvelles entreprises biotechnologiques axées sur le développement de programmes de médicaments anticorps. Le partenariat vise à créer des actifs dans le domaine de l'immunologie, avec Viking et ArrowMark supervisant la sélection et le financement des programmes, tandis qu'AbCellera met à profit son expertise dans la découverte et le développement de médicaments anticorps. Les programmes réussis mèneront à la création de nouvelles entreprises, avec AbCellera agissant en tant que partenaire fondateur en actions.
AbCellera, Viking Global Investors und ArrowMark Partners haben zusammengearbeitet, um neue Biotech-Unternehmen zu gründen, die sich auf die Weiterentwicklung von Antikörper-Medikamentenprogrammen konzentrieren. Die Partnerschaft zielt darauf ab, Vermögenswerte im Bereich der Immunologie zu schaffen, wobei Viking und ArrowMark die Auswahl und Finanzierung von Programmen überwachen, während AbCellera seine Expertise in der Entdeckung und Entwicklung von Antikörper-Medikamenten einsetzt. Erfolgreiche Programme führen zur Gründung neuer Unternehmen, wobei AbCellera als Equity-Gründungspartner teilnimmt.
Positive
  • Collaboration between AbCellera, Viking Global Investors, and ArrowMark Partners to advance new antibody drug programs and launch biotech companies.

  • Focus on addressing unmet medical needs in autoimmune disorders and other diseases through innovative medicines.

  • Utilization of AbCellera's technology and expertise in antibody discovery and development to accelerate program advancement.

  • Creation of Newcos through successful programs, with Viking and ArrowMark funding work through to company launch.

Negative
  • Potential challenges in program development, including clinical trial uncertainties and regulatory hurdles.

  • Risks associated with biotech investments such as delays in product development or failure of programs.

  • Possible dilution of shares for AbCellera shareholders due to equity participation in the new companies.

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL), Viking Global Investors (“Viking”), and ArrowMark Partners (“ArrowMark”) announced today that they have entered into a collaboration to advance new antibody drug programs with an aim to launch multiple asset-based companies. The first two programs will be in the area of immunology.

The collaboration brings together Viking and ArrowMark’s expertise in early-stage investing and company creation with AbCellera’s engine for discovering and developing antibody medicines. Under the collaboration, ArrowMark and Viking will lead the initial process of program selection, followed by joint determination of the therapeutic product profile and AbCellera’s initiation of new antibody drug programs. AbCellera will advance programs to development candidates and has an option to conduct cGMP manufacturing to support Phase 1 clinical trials. Successful programs will be further developed through the creation of Newcos, with Viking and ArrowMark funding work through to company launch.

“The next generation of drug targets requires the best technology to unlock their potential. We aim to address the significant unmet medical need in the lives of patients struggling with autoimmune disorders and other diseases,” said Tony Yao, M.D., Ph.D., Life Science Portfolio Manager at ArrowMark. “AbCellera is the proven technology leader in the space, and with its full, in-house drug development capabilities it can advance programs from concept to IND-enabling studies with speed and precision.”

"Successful biotech companies are created from a special alchemy of science, business, technology, talent, and capital,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “Our strategic alliance with Viking and ArrowMark brings strong relationships and complementary strengths to a common mission — launching new companies and creating innovative new medicines that move the needle for patients in need."

Under the terms of the collaboration, Viking and ArrowMark will be majority shareholders of the Newcos, and AbCellera will participate as an equity founding partner with the potential for milestones and royalties on future sales of each product.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.

About ArrowMark Partners

ArrowMark Partners is a privately held, employee-owned investment management firm founded in 2007 and headquartered in Denver, Colorado. Unified by a fundamental, research-driven philosophy and integrated investment platform, we focus on niche and less efficient market segments in public and private credit and equity, leveraged loans, and middle-market commercial real estate finance where our size, agility, and specialized expertise can deliver differentiated investing outcomes for clients.

AbCellera Forward-Looking Statements

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors are described under “Risk Factors,” “Management's Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Inquiries

Media: Kathleen Reid; media@abcellera.com, +1(236)521-6774

Business Development: Murray McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005

Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116

Source: AbCellera Biologics Inc.

FAQ

What is the collaboration between AbCellera, Viking Global Investors, and ArrowMark Partners about?

AbCellera, Viking Global Investors, and ArrowMark Partners have collaborated to launch new biotech companies focusing on advancing antibody drug programs.

What areas will the first two programs focus on?

The first two programs will be in the area of immunology.

What role will AbCellera play in the collaboration?

AbCellera will leverage its technology for discovering and developing antibody medicines and advance programs to development candidates.

Who will lead the initial process of program selection?

ArrowMark and Viking will lead the initial process of program selection.

What will happen to successful programs under the collaboration?

Successful programs will lead to the creation of Newcos, with Viking and ArrowMark funding work through to company launch.

AbCellera Biologics Inc. Common Shares

NASDAQ:ABCL

ABCL Rankings

ABCL Latest News

ABCL Stock Data

827.03M
208.65M
27.93%
39.78%
5.39%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
VANCOUVER